ACRS - Aclaris Therapeutics, Inc.
IEX Last Trade
2.905
1.715 59.036%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:00:00 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
19.80%
PREVIOUS CLOSE
CHG
CHG%
$1.19
1.72
144.12%
Fundamental analysis
20%
Profitability
0%
Dept financing
7%
Liquidity
75%
Performance
30%
Performance
5 Days
6.62%
1 Month
-27.32%
3 Months
158.93%
6 Months
124.81%
1 Year
171.03%
2 Year
-80.71%
Key data
Stock price
$2.90
DAY RANGE
$1.19 - $2.90
52 WEEK RANGE
$1.00 - $5.17
52 WEEK CHANGE
$173.58
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Neal S. Walker
Region: US
Website: aclaristx.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: aclaristx.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Aclaris Therapeutics, Inc. develops novel drug candidates for immune-inflammatory diseases in the United States. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa.
Recent news